UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States

Background: The efficacy and safety of UVA1 (340–400 nm) phototherapy were established by studies from European countries. Purpose: Evaluate experience with UVA1 phototherapy for patients with cutaneous diseases in the United States. Methods: A retrospective analysis of 92 cases of UVA1‐treated cutaneous conditions from four medical centers in the United States was performed. Results: Two‐third of the patients showed a fair to good response (26–100% improvement) and one‐third of the patients showed a poor response (0–25% improvement). Diseases with a moderate to good response (51–100% improvement) included scleredema adultorum, hand or foot dermatitis, atopic dermatitis, morphea (medium or medium‐ to high‐dose UVA1), systemic sclerosis, and urticaria pigmentosa. Besides tanning, other adverse effects were found in 15% of patients, which include pruritus, erythema, tenderness, and burning sensation. Patients with skin types I–III responded better that those with a darker skin type. Conclusion: UVA1 phototherapy is a useful and well‐tolerated treatment option for a variety of skin conditions.